Exbio — Research products — Antibodies — MHC antigens — Anti-HLA-B7 Purified

Anti-HLA-B7 Purified

Regulatory status

RUO

Antigen

HLA-B7

Clone

BB7.1

Format

Purified

Reactivity

Non-human primates, Human

Application

FC (QC tested)

Variant

0.1 mg

11-547-C100

Ask for delivery term HERE

154.00 USD

0.025 mg

11-547-C025

Delivery 1 week

77.00 USD

Variant

0.1 mg

11-547-C100

Ask for delivery term HERE

154.00 USD

0.025 mg

11-547-C025

Delivery 1 week

77.00 USD

Contact distributor

Product details

Description

Images

References

SDS download

Isotype

Mouse IgG1

Specificity

The mouse monoclonal antibody BB7.1 recognizes an extracellular antigen of HLA-B7 antigen. Although highly specific, it can cross-react with HLA-B42 antigen.

Application

FC (QC tested)

Application details

Flow cytometry: Recommended dilution: 1-4 μg/ml.

Reactivity

Non-human primates, Human

Immunogen

Papain solubilised HLA-A2, B7

Concentration

1 mg/ml

Preparation

Purified by protein-A affinity chromatography.

Formulation

Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

Storage and handling

Store at 2-8°C. Do not freeze.

The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.

Antigen description

HLA-B7 allele of human HLA class I major histocompatibility (MHC) antigen indicates higher risk of breast cancer and cervical cancer. Expression of HLA-B7 together with HLA-B27 is associated with increased susceptibility to spondyloarthropaties. Flow cytometry detection of these two alleles is being used to screen for patients, who suffer from inflammatory disorders affecting the sacroiliac and intervertebral joints, such as ankylosing spondylosis (AS). The HLA-B7 antigen (11 alleles) is expressed in 22% of healthy Caucasian individuals.

Separation of human lymphocytes of HLA-B7 positive blood donor (red-filled) from human lymphocytes of HLA-B7 negative blood donor (black-dashed) in flow cytometry analysis (surface staining) of human peripheral whole blood samples stained using anti-HLA-B7 (BB7.1) purified antibody (concentration in sample 2 μg/ml, GAM APC).

Flow cytometry surface staining patterns of human peripheral whole blood of HLA-B7 positive (left) and negative (right) blood donors stained using anti-HLA-B7 (BB7.1) purified antibody (concentration in sample 2 μg/ml, GAM APC).

General references:

Harjacek M, Margetić T, Kerhin-Brkljacić V, Martinez N, Grubić Z: HLA-B*27/HLA-B*07 in combination with D6S273-134 allele is associated with increased susceptibility to juvenile spondyloarthropathies. Clin Exp Rheumatol. 2008 May-Jun;26(3):498-504.
PubMed

Wang SS, Wheeler CM, Hildesheim A, Schiffman M, Herrero R, Bratti MC, Sherman ME, Alfaro M, Hutchinson ML, Morales J, Lorincz A, Burk RD, Carrington M, Erlich HA, Apple RJ: Human leukocyte antigen class I and II alleles and risk of cervical neoplasia: results from a population-based study in Costa Rica. J Infect Dis. 2001 Nov 15;184(10):1310-4.
PubMed

Grunewald J, Eklund A, Olerup O: Human leukocyte antigen class I alleles and the disease course in sarcoidosis patients. Am J Respir Crit Care Med. 2004 Mar 15;169(6):696-702.
PubMed

Bhattacharya P, Sengupta S: Predisposition to HPV16/18-related cervical cancer because of proline homozygosity at codon 72 of p53 among Indian women is influenced by HLA-B*07 and homozygosity of HLA-DQB1*03. Tissue Antigens. 2007 Oct;70(4):283-93.
PubMed

Product specific references:

Nabel GJ, Nabel EG, Yang ZY, Fox BA, Plautz GE, Gao X, Huang L, Shu S, Gordon D, Chang AE: Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11307-11.
PubMed

Worley BS, van den Broeke LT, Goletz TJ, Pendleton CD, Daschbach EM, Thomas EK, Marincola FM, Helman LJ, Berzofsky JA: Antigenicity of fusion proteins from sarcoma-associated chromosomal translocations. Cancer Res. 2001 Sep 15;61(18):6868-75.
PubMed

Storkus WJ, Alexander J, Payne JA, Dawson JR, Cresswell P: Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes. Proc Natl Acad Sci U S A. 1989 Apr;86(7):2361-4.
PubMed

de la Salle H, Saulquin X, Mansour I, Klayme S, Fricker D, Zimmer J, Cazenave JP, Hanau D, Bonneville M, Houssaint E, Lefranc G, Naman R: Asymptomatic deficiency in the peptide transporter associated to antigen processing (TAP). Clin Exp Immunol. 2002 Jun;128(3):525-31.
PubMed

Lo Monaco E, Sibilio L, Melucci E, Tremante E, Suchànek M, Horejsi V, Martayan A, Giacomini P: HLA-E: strong association with beta2-microglobulin and surface expression in the absence of HLA class I signal sequence-derived peptides. Immunol. 2008 Oct 15;181(8):5442-50.
PubMed

Hofmann S, Glückmann M, Kausche S, Schmidt A, Corvey C, Lichtenfels R, Huber C, Albrecht C, Karas M, Herr W: Rapid and sensitive identification of major histocompatibility complex class I-associated tumor peptides by Nano-LC MALDI MS/MS. Mol Cell Proteomics. 2005 Dec;4(12):1888-97.
PubMed

Cortez-Gonzalez X, Sidney J, Adotevi O, Sette A, Millard F, Lemonnier F, Langlade-Demoyen P, Zanetti M: Immunogenic HLA-B7-restricted peptides of hTRT. Int Immunol. 2006 Dec;18(12):1707-18.
PubMed

Rini BI, Selk LM, Vogelzang NJ: Phase I study of direct intralesional gene transfer of HLA-B7 into metastatic renal carcinoma lesions. Clin Cancer Res. 1999 Oct;5(10):2766-72.
PubMed